Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07337655 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial
A Phase 2 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 670
- Enrollment target
NCT07337655: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT07337655 is a Phase 2 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 670 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07337655, a Phase 2 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 670 participants
- Enrollment target
Study Summary
This protocol describes a seamless Phase II/III, randomized, double-blind clinical trial evaluating the efficacy and safety of daily low-dose aspirin (81 mg) plus lansoprazole (30 mg) in pregnant individuals at high risk for preterm birth when compared to existing standard of care, identified through biomarker-enriched screening. Participants will be enrolled between 12-16+6 weeks' gestation and followed through delivery and postpartum. The primary objective is to determine whether the investigational combination reduces the incidence of preterm birth before 37 weeks of gestation compared with placebo.
Interventions
- OTHER Standard of Care
- DRUG Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2032-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07337655
The ClinicalTrials.gov registry entry for NCT07337655 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT07337655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07337655 about?
NCT07337655 is a clinical study titled "Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial". This protocol describes a seamless Phase II/III, randomized, double-blind clinical trial evaluating the efficacy and safety of daily low-dose aspirin (81 mg) plus lansoprazole (30 mg) in pregnant individuals at high risk for preterm birth when compared to existing standard of care, identified throug...
What is the current status of trial NCT07337655?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 670 participants. The study started on 2026-10-01. Estimated completion is 2032-09-30.
What interventions are being tested in trial NCT07337655?
The interventions under investigation include: Standard of Care (OTHER), Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg (DRUG).
Who is sponsoring clinical trial NCT07337655?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.